1621255-92-2

Upstream product

• 1621255-91-1 methyl 3'-iodo-4'-methoxy-2-(trifluoromethyl)biphenyl-4-carboxylate 
• 73183-34-3 bis(pinacol)diborane 
• 1621255-90-0 methyl 4'-methoxy-2-(trifluoromethyl)biphenyl-4-carboxylate 
• 107317-58-8 4-bromo-3-trifluoromethylbenzoic acid methyl ester 
• 5720-07-0 4-methoxyphenylboronic acid 

Downstream Products

• 1621255-93-3 methyl 3'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4'-methoxy-2-(trifluoromethyl)biphenyl-4-carboxylate 
• 1621254-56-5 3'-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4'-methoxy-2-(trifluoromethyl)biphenyl-4-carboxylic acid 

Relevant academic research and scientific papers

BIARYL- OR HETEROCYCLIC BIARYL-SUBSTITUTED CYCLOHEXENE DERIVATIVE COMPOUNDS AS CETP INHIBITORS

The present invention provides biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds, isomers thereof, or pharmaceutically acceptable salts. The compounds of the invention show a CETP inhibitory effect that increases HDL-cholesterol levels and reduces LDL-cholesterol levels. Pharmaceutical compositions comprising the compounds are useful for the prevention or treatment of dyslipidemia or dyslipidemia-related diseases.